After decades in dermatology, board-certified brothers Dr. Ben Behnam and Dr. Sean Behnam began noticing the same frustration echoed by patient after patient: hair loss treatments felt more like trial and error than medical care. Many had cycled through shampoos, supplements and prescriptions that promised regrowth but delivered little lasting improvement. To the Behnams, the problem was clear — hair loss was being treated as a consumer product, not a chronic medical condition requiring ongoing, personalized care.
That insight led to the launch of Happy Head in 2021, a telemedicine company offering dermatologist-prescribed, customized hair growth treatments delivered directly to patients’ homes. The timing coincided with the COVID-19 pandemic, when virtual healthcare rapidly shifted from a convenience to a necessity.
A medical-first approach to hair loss
Unlike mass-market hair loss brands built around standardized formulas, Happy Head begins with a medical evaluation. Patients complete a digital consultation reviewed by licensed clinicians, with board-certified physicians guiding treatment decisions. Prescriptions are custom-compounded, combining medications at specific strengths tailored to each individual rather than offering a one-size-fits-all solution.
That distinction is deliberate, according to Benjamin Katz, a serial entrepreneur and registered nurse who acquired majority ownership of Happy Head shortly after its launch. Katz says the company draws heavily on clinical dermatology practices, including medications widely used in Europe but less familiar to U.S. consumers, and adapts them based on each patient’s needs.
“Most hair loss treatments are impersonal,” Katz says. “We’re building what dermatologists actually do in practice into a telemedicine model.”
A premium price for specialized care
Happy Head costs roughly $500 more per year than many competitors, positioning the company firmly in the premium segment of the market. Katz is unapologetic about the pricing, noting that the brand is designed for high earners who value specialized medical care.
“It’s the difference between a Toyota and a Lamborghini,” he says. “We’re optimized for people who are willing to invest in their appearance and their health, and who want a dermatologist involved — not just a generic prescription.”
Beyond prescriptions
The company has expanded beyond core hair growth medications to offer genetic testing, laser therapy devices, and supportive products such as shampoos, conditioners, serums and vitamins. Its genetic analysis tool, StrandIQ, is designed to identify which ingredients are most likely to be effective based on an individual’s genetic markers. The test often attracts customers in their 20s, allowing them to take a proactive approach before visible hair loss or graying begins.
Happy Head is also entering the prescription dandruff treatment market, which Katz believes is underserved. Many consumers rely solely on over-the-counter solutions, which he argues are far less effective than prescription-strength therapies.
To help patients stay motivated, the company encourages users to submit hairline photos between months three and six of treatment, creating a visual timeline of progress. “You don’t notice change day to day,” Katz says. “But when you look back at a proper time series, the growth becomes clear.”
Competing in a crowded telemedicine market
Happy Head faces stiff competition from publicly traded companies such as Hims & Hers and venture-backed platforms like Ro, all of which operate with massive marketing budgets. The influx of capital into telemedicine — known in part by the rise of GLP-1 weight loss drugs like Ozempic — has intensified competition across the sector.
Katz says Happy Head’s ownership structure sets it apart. The company operates more like a family office, primarily owned by healthcare providers, with no intention of pursuing growth at all costs. That philosophy is shaped by Katz’s own experience. At a previous company, a vendor crisis led to a year without revenue, followed by a down round that ultimately cost him control of the business.
“That experience made me want to build companies that are sustainable and profitable,” he says.
Rather than expanding into adjacent categories like erectile dysfunction or general wellness, Happy Head remains tightly focused on hair and scalp health.
Playing the long game
Hair loss affects more than 50 million men and 30 million women in the U.S., but not every patient responds to treatment. About one in nine users sees little improvement, according to Katz. When that happens, Happy Head investigates why, adjusting medications, switching between topical and oral treatments, and examining lifestyle factors such as diet, sleep and stress.
“Your body is a system,” Katz says. “Before changing a prescription, we often start with basics like protein intake, vitamin D and collagen.”
That long-term mindset defines Happy Head’s strategy. The company has already captured market share comparable to Hims and Ro among high-income customers — precisely the demographic it targets.
“I believe in long-term compounding,” Katz says. “If we stay the best-in-class hair medicine player online, there will always be room for us to grow.”
